Clinical effect of the anti-platelet drug, dilazep dihydrochloride, in patients at the microalbuminuric stage of diabetic nephropathy--a multi-center study.
Clinical effects of an anti-platelet drug (dilazep dihydrochloride) in the microalbuminuric stage of diabetic nephropathy were investigated in a multi-center study. Thirty-seven patients with at the microalbuminuric stage of diabetic nephropathy were examined in the present study. They were administered 300 mg/day of dilazep dihydrochloride (Comelian-Kowa) orally for 6 months. Mean values of albuminuria after the administration of dilazep dihydrochloride were significantly decreased compared with the pre-administration values. Urinary NAG activity was improved after this treatment in the microalbuminuric stage of diabetic nephropathy. Furthermore, impairment of renal function was not observed at that stage. It appears that administration of dilazep dihydrochloride from the early stage of diabetic nephropathy may be useful for the improvement of albuminuria and prevention of renal dysfunction.
Koide
H
H
Department of Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Totsuka
Y
Y
Sugisaki
T
T
Kitajima
T
T
Ohmori
Y
Y
Kuriyama
S
S
Oi
K
K
Isogai
S
S
Ohi
H
H
Tomino
Y
Y
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000652:urine; D004109:Dilazep / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*
D010975:Platelet Aggregation Inhibitors; D004109:Dilazep